A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world

BACKGROUND: Roflumilast is approved in the United States to reduce the risk of COPD exacerbations in patients with severe COPD. Exacerbation rates, health care resource utilization (HCRU), and costs were compared between roflumilast patients and those receiving other COPD maintenance drugs. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Yin, Sun, Shawn X, Corman, Shelby, Huang, Xingyue, Gao, Xin, Shorr, Andrew F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603715/
https://www.ncbi.nlm.nih.gov/pubmed/26504378
http://dx.doi.org/10.2147/COPD.S80106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603715/
https://www.ncbi.nlm.nih.gov/pubmed/26504378
http://dx.doi.org/10.2147/COPD.S80106

Ejemplares similares